NCT06492226已完成1 期
A Single-center, Single-dose, Double-blind, Randomized, Three-period, Three-treatment, Six-sequence, Crossover Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid® Using the Euglycemic Clamp Technique in Healthy Male Adult Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- To compare the PD of NKF-INS(A) to US-approved and EU-authorized insulin aspart injection by examining GIR profiles after a single SC dose.
研究概览
简要总结
Single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®
详细描述
A single-center, single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS(A), US-NovoLog®, and EU-NovoRapid® using the euglycemic clamp technique in healthy male adult volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Signed and dated informed consent obtained before any trial-related activities. Trial-related activities are any procedures that would not have been done during normal management of the participant
- •Healthy male participants
- •Age between 18 and 50 years, both inclusive
- •Body Mass Index between 18.5 and 29.0 kg/m2, both inclusive
- •Body weight ≥ 50 kg
- •Fasting plasma glucose concentration ≤ 5.5 mmol/L at screening
- •Considered generally healthy upon completion of medical history, physical examination, vital signs, electrocardiogram (ECG), and analysis of laboratory safety variables, as judged by the Investigator
- •Willing and able to comply with scheduled visits, treatment plan, clinical laboratory tests, and other study procedures including lifestyle considerations.
- •Participants must agree to use condoms during sexual intercourse. Additionally, female partners of male participants should use highly effective contraception. All contraceptive measures apply from screening until 90 days after study
- •Have competence in speaking, writing, and comprehending the local language(s) where the study is conducted.
排除标准
- •Positive for human insulin antibodies at Screening
- •Are currently enrolled in or have discontinued within 3 months or 5 half-lives (whichever is longer) of any investigational drug or device or are concurrently enrolled in any other type of medical research study and judged not to be scientifically or medically compatible with this study.
- •Have known allergies to insulin, its excipients, or related drugs or have history of relevant allergic reactions of any origin.
- •History of diabetes mellitus; episodes of hypoglycemia in the anamnesis; any history of insulin use for treatment purposes.
- •Have known allergies to insulin, its excipients, or related drugs or have history of relevant allergic reactions of any origin.
- •Have clinically relevant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data.
- •Increased risk of thrombosis, e.g., individuals with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator.
- •Clinically significant abnormal ECG at screening.
- •Glycemia level ≥140.4 mg/dL 2 hours after the glucose load.
- •Show evidence of significant active neuropsychiatric disease.
- •Positive urine drug test at screening and/or evidence of current use of known drugs of abuse or have a history of use within the past year.
- •Show evidence of an acute infection with fever or infectious disease at the time of enrollment.
- •Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies at screening.
- •Have positive test results for hepatitis B surface antigen (HBsAg), immunoglobulin M (IgM) antibody to hepatitis B core antigen (anti-HBc), or hepatitis C virus (HCV) antibodies at screening.
- •Intend to use over-the-counter medication within 7 days or prescription medication within 14 days prior to dosing (apart from vitamin/mineral supplements, occasional paracetamol, thyroid replacement).
- •Have donated blood or had a blood loss of 450 mL 3 months prior to study enrollment.
- •Have an average weekly alcohol intake that exceeds 21 units per week or is unwilling to stop alcohol consumption from 48 hours prior to each dosing until being discharged from the CRU.
研究组 & 干预措施
NKF-INS(A)
Experimental
Single subcutaneous dose administration over three treatment periods
干预措施: NKF-INS(A) (Drug)
EU-NovoRapid®
Active Comparator
Single subcutaneous dose administration over three treatment periods
干预措施: EU-NovoRapid® (Drug)
US-NovoLog®
Active Comparator
Single subcutaneous dose administration over three treatment periods
干预措施: US-NovoLog® (Drug)
结局指标
主要结局
To compare the PD of NKF-INS(A) to US-approved and EU-authorized insulin aspart injection by examining GIR profiles after a single SC dose.
时间窗: Day 1 for 12 Hours
Maximum GIR (GIRmax) of glucose
To compare the PK of NKF-INS(A) to US-approved and EU-authorized insulin aspart to demonstrate PK similarity for insulin aspart.
时间窗: Day 1 for 12 Hours
Maximum observed insulin aspart concentration (Cmax)
次要结局
- To evaluate additional PK parameters of NKF-INS(A) compared to US-approved and EU-authorized insulin aspart.(Day 1 for 12 Hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human SubjectsPharmacokineticsNCT05452785Journey Medical Corporation24
已完成
1 期
Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted ConditionsPharmacokineticsNCT02561741Mallinckrodt30
已完成
1 期
Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted ConditionsPharmacokineticsNCT02561650Mallinckrodt48
已完成
1 期
A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy AdultsHealthyNCT05319912Alexion Pharmaceuticals, Inc.18
已完成
1 期
A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy AdultsHealthyNCT05319899Alexion Pharmaceuticals, Inc.18